Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Early trial data showed that treatment with the antibiotic ceftriaxone is unlikely to affect survival time or symptom progression in ALS
Posted on Wednesday, August 8, 2012 - 12:02, By: Amy Madsen
On Aug. 8, 2012, the National Institute of Neurological Disorders and Stroke (NINDS) reported that it has stopped a phase 3 clinical trial of the antibiotic ceftriaxone in amyotrophic lateral sclerosis (ALS) because the study was "unlikely to reach the predetermined efficacy criteria."
Investigators on a study of ceftriaxone in amyotrophic lateral sclerosis (ALS) will host an informational webinar Tuesday, Sept. 7, 2010
Login information for webinar changed 9/1/10
Posted on Wednesday, September 1, 2010 - 14:14, By: Margaret Wahl
Editor's note: The information on joining this webinar has been updated, per the presenters, Sept. 1, 2010.
A clinical trial of the drug ceftriaxone in amyotrophic lateral sclerosis (ALS) is currently recruiting participants at 54 locations across the United States and Canada. (...
A 600-person trial of intravenous ceftriaxone in ALS is still looking for participants at 53 North American sites
Posted on Friday, June 11, 2010 - 11:23, By: Margaret Wahl
A 600-person trial of intravenous ceftriaxone, an antibiotic in the cephalosporin family that's approved to treat certain types of infections, is still looking for participants at 53 sites in the United States and Canada.
About the trial
Laboratory studies have suggested that ceftriaxone protects...
Posted on Thursday, November 1, 2007 - 09:16, By: Margaret Wahl
New studies strongly support ALS-angiogenin connection
A study conducted by investigators at several institutions in Boston has added additional support to an existing hypothesis based on earlier studies that mutations in the gene for angiogenin can cause ALS, or at least increase susceptibility to...